Search details
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Article
in English
| MEDLINE | ID: mdl-34953525
3.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Article
in English
| MEDLINE | ID: mdl-35411939
4.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35671327
5.
The Lancet Commission on prostate cancer: planning for the surge in cases.
Lancet
; 403(10437): 1683-1722, 2024 Apr 27.
Article
in English
| MEDLINE | ID: mdl-38583453
6.
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
Res Sq
; 2023 Feb 08.
Article
in English
| MEDLINE | ID: mdl-36798177
7.
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PLoS One
; 17(6): e0269192, 2022.
Article
in English
| MEDLINE | ID: mdl-35653395
8.
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Article
in English
| MEDLINE | ID: mdl-35877084
9.
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
J Clin Oncol
; 40(8): 825-836, 2022 03 10.
Article
in English
| MEDLINE | ID: mdl-34757812
10.
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience.
Ther Adv Med Oncol
; 12: 1758835920956803, 2020.
Article
in English
| MEDLINE | ID: mdl-32968429
11.
Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions.
J Hepatocell Carcinoma
; 6: 11-21, 2019.
Article
in English
| MEDLINE | ID: mdl-30643759
12.
Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
Eur Urol
; 85(6): e164-e165, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38584074
13.
Testing alternative schedules of adjuvant immune checkpoint blockers - The need for well-designed clinical trials.
Eur J Cancer
; 178: 88-90, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36427393
Results
1 -
13
de 13
1
Next >
>>